Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by stock analysts at Wells Fargo & Co from an “overweight” rating to an “equal weight” rating in a report issued on Monday, MarketBeat reports. They currently have a $46.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $146.00. Wells Fargo & Co‘s price target indicates a potential downside of 3.99% from the company’s previous close.
A number of other equities research analysts have also weighed in on the company. B. Riley reiterated a “buy” rating and issued a $158.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, May 22nd. Royal Bank of Canada reiterated a “buy” rating and issued a $117.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, April 8th. Bank of America assumed coverage on Intercept Pharmaceuticals in a research report on Thursday, March 5th. They issued a “neutral” rating and a $111.00 price objective on the stock. BidaskClub upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $227.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, May 22nd. Eighteen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $81.48.
ICPT opened at $47.91 on Monday. The stock’s 50 day simple moving average is $78.84 and its 200 day simple moving average is $88.09. The company has a debt-to-equity ratio of 10.32, a current ratio of 4.19 and a quick ratio of 4.19. Intercept Pharmaceuticals has a 1 year low of $44.50 and a 1 year high of $125.00. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of -4.47 and a beta of 1.82.
In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 595,578 shares of Intercept Pharmaceuticals stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $84.60, for a total transaction of $50,385,898.80. Following the completion of the transaction, the director now owns 19,433 shares in the company, valued at $1,644,031.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 595,817 shares of company stock valued at $50,405,516 in the last quarter. 23.70% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the business. Public Employees Retirement Association of Colorado raised its stake in Intercept Pharmaceuticals by 20.9% during the first quarter. Public Employees Retirement Association of Colorado now owns 4,290 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 742 shares during the last quarter. Sarissa Capital Management LP raised its stake in Intercept Pharmaceuticals by 34.3% during the first quarter. Sarissa Capital Management LP now owns 1,155,000 shares of the biopharmaceutical company’s stock valued at $72,718,000 after buying an additional 295,000 shares during the last quarter. Twinbeech Capital LP purchased a new position in Intercept Pharmaceuticals during the first quarter valued at $928,000. Advisor Group Holdings Inc. purchased a new position in Intercept Pharmaceuticals during the first quarter valued at $4,732,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Intercept Pharmaceuticals in the first quarter worth $1,467,000. Institutional investors and hedge funds own 76.46% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Story: What causes a recession?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.